W. R. Berkley
WRB
$65.70
-2.25%
W.R. Berkley Corporation is a diversified insurance holding company that primarily underwrites commercial casualty insurance through a host of subsidiaries. The firm operates in the Property & Casualty insurance industry, specializing in niche products including excess and surplus lines, workers' compensation, reinsurance, and regional commercial lines for small and midsize businesses. It is a well-established, disciplined underwriter known for its focus on specialty and niche markets, which provides a degree of insulation from broader competitive pressures. The current investor narrative centers on the company's ability to navigate a potentially softening insurance pricing cycle, as evidenced by recent quarterly results showing a sequential decline in net income, while maintaining its underwriting discipline and capital return strategy.…
WRB
W. R. Berkley
$65.70
Investment Opinion: Should I buy WRB Today?
Rating: Hold. The core thesis is that WRB is a high-quality insurer facing near-term cyclical headwinds; its attractive valuation and strong balance sheet provide a margin of safety, but absent a catalyst for earnings re-acceleration, the stock is likely to remain range-bound. This aligns with the mixed but generally neutral analyst sentiment (Neutral/Hold from several major firms).
Supporting evidence includes a forward P/E of 13.64x, which is reasonable for a company with an 18.34% ROE. The price-to-book of 2.87x, while elevated historically, is supported by that high profitability. The company generates substantial cash, with TTM FCF of $3.43B supporting its dividend (yield of 2.52%). However, the deteriorating momentum in net income (-12% QoQ) and the stock's severe underperformance (-9.15% in 1 month) counterbalance these valuation positives.
The thesis would upgrade to a Buy if the forward P/E compressed below 12x on sustained earnings, or if quarterly results show a stabilization and sequential improvement in net income and margins, signaling the cycle trough. It would downgrade to a Sell if the stock breaks below $62.63 support on worsening fundamentals, or if net margin compresses further below 11%. Relative to its own history and the current growth profile, the stock appears fairly valued, balancing quality against cyclical risk.
Sign up to view all
WRB 12-Month Price Forecast
WRB presents a classic 'wait and see' scenario. The quality of the franchise is undeniable, evidenced by its high ROE and pristine balance sheet. However, the near-term fundamental momentum is negative, and the stock's price action confirms this deterioration. The base case of range-bound trading is most probable, as the market digests the cyclical slowdown. The stance would upgrade to bullish on concrete evidence of margin stabilization or a valuation drop below a 12x forward P/E. It would turn bearish on a breakdown below the $62.63 support level, which would signal a new phase of multiple contraction.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on W. R. Berkley's 12-month outlook, with a consensus price target around $85.41 and implied upside of +30.0% versus the current price.
Average Target
$85.41
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$53 - $85
Analyst target range
Analyst coverage appears limited, with only two analysts providing estimates for revenue and EPS, which is unusually low for a company of this size and suggests it may be under-followed by the broader sell-side community. The estimated EPS range for the forward period is tight, from $5.04 to $5.17, with an average of $5.11, while the revenue estimate averages $14.35 billion. Institutional ratings from recent months show a mixed but generally neutral-to-cautious sentiment, with firms like BofA, Mizuho, Jefferies, and Wells Fargo maintaining 'Neutral' or 'Hold' ratings, while Cantor Fitzgerald and Argus maintain 'Overweight' or 'Buy' ratings; notably, TD Cowen downgraded the stock to 'Sell' from 'Hold' in January 2026. The lack of a published consensus price target in the data and the minimal analyst count imply higher uncertainty and potentially less efficient price discovery, which can contribute to the stock's recent elevated volatility relative to its historical beta.
Bulls vs Bears: WRB Investment Factors
The evidence currently tilts bearish, driven by the accelerating technical downtrend and clear signs of fundamental deterioration in profitability. The bull case rests on a high-quality, conservatively financed business trading at a reasonable valuation, while the bear case is fueled by near-term earnings pressure and negative momentum. The single most important tension in the investment debate is whether WRB's renowned underwriting discipline can defend margins and return to earnings growth in the face of what appears to be a softening industry pricing cycle. The resolution of this tension in upcoming quarters will determine the stock's direction.
Bullish
- Strong Underlying Profitability: The company maintains a robust Return on Equity of 18.34%, significantly above typical industry benchmarks, indicating efficient use of shareholder capital. This is supported by a trailing twelve-month free cash flow of $3.43 billion, providing ample resources for dividends, buybacks, and strategic investments.
- Conservative Financial Position: WRB's balance sheet is a key strength, with a low debt-to-equity ratio of 0.29 and a healthy current ratio of 1.39. This low leverage provides significant financial flexibility to navigate market cycles and pursue opportunities without external financing pressure.
- Attractive Valuation on Earnings: The stock trades at a forward P/E of 13.64x, which is a discount to its trailing P/E of 15.63x, suggesting the market has already priced in earnings pressure. This valuation is in the mid-range of its recent historical P/E, indicating it is not priced for perfection.
- Niche Market Focus: The company's specialization in excess & surplus lines and regional commercial insurance provides a degree of insulation from broader competitive pressures. This disciplined underwriting approach in niche markets is a long-term structural advantage.
Bearish
- Accelerating Fundamental Deterioration: Profitability is under clear pressure, with Q4 2025 net income declining 12% sequentially from $511M to $450M, and the net margin compressing from 13.56% to 12.09%. This sequential decline in a key metric is a major red flag for near-term earnings trajectory.
- Pronounced and Persistent Price Downtrend: The stock is down 9.15% over the past month and 14.14% over six months, starkly underperforming the S&P 500 by 27.59% over the past year. Trading at 84% of its 52-week range near the low of $62.63 signals strong selling pressure and a lack of buyer conviction.
- Potential Softening Insurance Cycle: The investor narrative centers on navigating a softening pricing cycle, which is being confirmed by the margin compression. The gross margin of 20.58% in Q4 2025 is flat YoY but down from 25.25% in Q4 2024, indicating top-line pricing power may be waning.
- Limited Analyst Coverage & Sentiment: With only two analysts providing estimates and a mix of recent 'Neutral/Hold' and 'Sell' ratings (including a TD Cowen downgrade to Sell), there is a lack of bullish catalysts and institutional support. The minimal coverage suggests higher uncertainty and less efficient price discovery.
WRB Technical Analysis
The stock is in a pronounced downtrend, having declined 5.39% over the past year, which starkly contrasts with the S&P 500's 22.2% gain, resulting in a relative strength deficit of 27.59%. As of the latest close of $65.99, the price is trading at approximately 84% of its 52-week range, positioned closer to the 52-week low of $62.63 than the high of $78.96, suggesting the stock is in a value zone but facing significant downward pressure. The short-term momentum is decisively negative, with the stock down 9.15% over the past month and 4.86% over the past three months, indicating the downtrend is accelerating rather than finding a base, especially as the 1-month decline outpaces the broader market's 4.28% drop. The stock's low beta of 0.373 signals it is historically less volatile than the market, but the recent sharp price action suggests idiosyncratic or sector-specific concerns are driving the weakness. Key technical support is clearly defined at the 52-week low of $62.63, while resistance lies near the recent highs around $78; a breakdown below $62.63 would signal a new leg down, whereas a recovery above the $70 level, which has acted as resistance, would be necessary to suggest the downtrend is abating.
Beta
0.37
0.37x market volatility
Max Drawdown
-17.8%
Largest decline past year
52-Week Range
$64-$79
Price range past year
Annual Return
-2.1%
Cumulative gain past year
| Period | WRB Return | S&P 500 |
|---|---|---|
| 1m | -3.2% | +0.5% |
| 3m | -4.0% | -2.1% |
| 6m | -15.4% | +4.0% |
| 1y | -2.1% | +29.5% |
| ytd | -5.3% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WRB Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $3.72 billion representing a 1.4% year-over-year increase; however, the trend across 2025 shows volatility, with revenue peaking in Q3 at $3.77 billion before the Q4 dip. The Domestic Insurance segment, at $3.04 billion in the latest period, is the primary revenue driver, significantly larger than the $455 million Global Reinsurance segment. Profitability has come under pressure, as evidenced by a sequential decline in net income from $511 million in Q3 2025 to $450 million in Q4 2025, with the net margin compressing from 13.56% to 12.09% over the same period; the gross margin also declined from 20.58% in Q4 2024 to 20.58% in Q4 2025, indicating potential margin headwinds. The company remains solidly profitable with a trailing twelve-month free cash flow of $3.43 billion and a strong return on equity of 18.34%. The balance sheet is conservatively managed with a low debt-to-equity ratio of 0.29 and a healthy current ratio of 1.39, providing ample liquidity and financial flexibility to weather the current soft patch without external financing needs.
Quarterly Revenue
$3.7B
2025-12
Revenue YoY Growth
+0.01%
YoY Comparison
Gross Margin
+0.20%
Latest Quarter
Free Cash Flow
$3.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WRB Overvalued?
Given the positive net income, the primary valuation metric is the P/E ratio. The stock trades at a trailing P/E of 15.63x and a forward P/E of 13.64x based on estimated EPS; the forward multiple being lower suggests the market anticipates earnings growth or reflects a discount due to recent fundamental pressures. Compared to its own historical range, the current trailing P/E of 15.63x is below the higher end seen in recent quarters (e.g., 18.17x in Q2 2025) but above the lows near 10.1x from late 2024, placing it in a mid-range historically, which implies the market is not pricing in extreme optimism nor pessimism. The price-to-sales ratio of 1.89x and price-to-book ratio of 2.87x provide additional context, with the P/B ratio sitting above the 2.57x seen at the end of 2023, indicating the market still assigns a premium to book value despite the price decline.
PE
15.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on earnings volatility and margin compression. The sequential 12% drop in Q4 net income and the 147 basis point compression in net margin from Q3 to Q4 highlight sensitivity to the insurance cycle. While revenue growth is modest at 1.4% YoY, the company's profitability is demonstrably under pressure. However, these risks are mitigated by a fortress balance sheet with a debt-to-equity of 0.29 and strong liquidity (current ratio of 1.39), eliminating solvency concerns.
Market & Competitive Risks include valuation compression and sector-specific headwinds. The stock's low beta of 0.373 suggests it is less correlated to the broad market, but its severe underperformance (-27.59% relative to SPY over 1 year) points to intense sector-specific selling. The primary risk is a prolonged soft market in commercial insurance, compressing underwriting margins further. The stock's P/B of 2.87x, while down from recent highs, still carries a premium that could contract if ROE continues to decline from its current 18.34%.
Worst-Case Scenario involves a deeper-than-expected downturn in the commercial P&C cycle, triggering consecutive quarters of double-digit earnings declines, analyst downgrades, and a loss of investor confidence in management's cycle-management abilities. This could lead the stock to breach its key technical support at the 52-week low of $62.63 and test lower valuation floors, potentially towards a P/E of 11-12x on reduced earnings. A realistic adverse scenario could see a decline of 15-20% from the current $65.99, pushing the stock into the low-$50s, which would represent a total peak-to-trough drawdown exceeding 30% from its 52-week high.
FAQ
The key risks are, in order of severity: 1) Cyclical/Earnings Risk: Further softening of the insurance pricing cycle, leading to more net income declines like the 12% sequential drop seen in Q4. 2) Price/Momentum Risk: The stock is in a strong downtrend, underperforming the market by 27.6% over the past year, which can erode capital in the near term. 3) Valuation Compression Risk: If ROE declines from 18.3%, the premium P/B multiple of 2.87x could contract sharply. 4) Limited Catalyst Risk: With sparse analyst coverage and neutral sentiment, there is a lack of near-term positive catalysts to drive the stock higher.
The 12-month forecast centers on a base case (60% probability) of range-bound trading between $66 and $72, as the company navigates a soft earnings period. The bull case (25% probability) targets $78-$82, requiring a quicker-than-expected turnaround in insurance pricing and margins. The bear case (15% probability) sees a drop to $55-$62 if the cycle worsens and earnings estimates are cut. The most likely scenario is the base case, which assumes earnings stabilize near current forward EPS estimates of $5.11 without a significant recovery in growth or multiples.
WRB appears fairly valued relative to its current fundamentals. Its forward P/E of 13.64x is a discount to its trailing P/E of 15.63x, reflecting expected earnings pressure. The price-to-book ratio of 2.87x is elevated but supported by a high return on equity of 18.34%. Compared to its own historical P/E range (from lows near 10x to highs above 18x), the current multiple is in the mid-range. The market is pricing in a moderate earnings slowdown but not a severe downturn. It is neither screamingly cheap nor excessively expensive.
WRB is a good buy for a specific type of investor: a patient, value-oriented investor looking for a high-quality business trading at a reasonable valuation during a cyclical slowdown. With a forward P/E of 13.6x and a strong ROE of 18.3%, it offers a margin of safety. However, it is not a good buy for those seeking near-term momentum or growth, as the stock is in a pronounced downtrend (-9.15% in 1 month) and profitability is under pressure. The biggest risk is further earnings deterioration, which could push the stock towards its 52-week low of $62.63 or lower.
WRB is unequivocally suited for a long-term investment horizon, with a minimum suggested holding period of 3-5 years to ride out the insurance cycle. Its low beta of 0.373 indicates lower volatility relative to the market, which is typical for a value stock, but the recent sector-specific selloff shows it is not immune to downturns. The company pays a reliable dividend (2.52% yield), supporting a total return approach for income-oriented investors. It is poorly suited for short-term trading given its negative momentum and lack of immediate growth catalysts.